Description 

Organs are vulnerable to environment outside the human body; hence, they are kept in preservation solutions that have a composition similar to that of human body fluids. These solutions are known as organ preservation solutions and are typically composed of ions, proteins and buffer solutions that help maintain a sustainable environment for organs.

The global organ preservation solutions market is estimated to account for US$ 238.7 Mn in terms of value in 2020 and is expected to reach US$ 695.0 Mn by the end of 2027.

Global Organ Preservation Solutions Market: Drivers

High number of organ transplant is expected to propel growth of the global organ preservation solutions market over the forecast period. For instance, according to the Organ Procurement and Transplantation Network (OPTN)/ The Scientific Registry of Transplant Recipients (SRTR), in 2015, 2016, and 2019, the U.S. recorded over 30,000 transplants per year.

Moreover, increasing incidences of chronic diseases is also expected to propel growth of the global organ preservation solutions market over the forecast period. For instance, according to the American Cancer Society, in 2019, there will be an estimated 1,762,450 new cancer cases diagnosed and 606,880 cancer deaths in the U.S.

Custodiol HTK held dominant position in the global organ preservation solutions market in 2019, accounting for 51.1% share in terms of value, followed by Viaspan and Perfadex, respectively.

Global Organ Preservation Solutions Market: Restraints

Advent of stem cells is expected to hinder growth of the global organ preservation solutions market. The need for organ transplantation could eventually be reduced by stem cell therapies. Scientists hope to repair/replace damaged organs with new cells grown from adult or embryonic stem cells. Therefore, increasing adoption of stem cell therapies could act as a restraint of the growth of the global organ preservation solutions market in the near future.

Moreover, high cost of procedure is also expected to limit growth of the global organ preservation solutions market. The cost of a kidney transplant procedure in the U.S. is around US$ 89,939. This is followed by medications for several years that cost around US$ 16,043 per year.

Organ Preservation Solutions Market Report Coverage

Base Year:  2019      

Market Size in 2019:  US$ 204.9 Mn

Historical Data for:  2016 to 2019     

Forecast Period:  2020 to 2027

Forecast Period: 2020 to 2027

CAGR:  16.5%    2027

Value Projection:  US$ 695.0 Mn

Geographies covered:  

• North America: U.S., Canada
• Latin America: Brazil, Argentina, Mexico, Rest of Latin America
• Europe: Germany, U.K., Spain, France, Italy, Russia, Rest of Europe
• Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, Rest of Asia Pacific
• Middle East: GCC Countries, Israel, Rest of Middle East
• Africa: South Africa, North Africa, Central Africa

Segments covered:        

• By Solution Type: Viaspan, Custodiol HTK, Renograf, Hypothermosol, Perfadex, Lifor, HBS Solution, siRNA Transplant Solutions, Others.
• By Technique Type: Hypothermic Perfusion Preservation, Static Cold Storage, Others.
• Companies covered:
• Teva Pharmaceutical Industries Ltd., Dr. Franz Köhler Chemie GmbH, BioLife Solutions, XVIVO Perfusion AB, Bristol-Myers Squibb, Inc., and ToleroTech, Inc., Lifeline Scientific, Preservation Solutions Inc., Claris Injectables Limited, 21st Century Medicine, Paragonix Technologies Inc., BioTime, Inc. CryoLife, Inc.

Growth Drivers:              

• Increasing prevalence of diseases
• Increasing demand for organ transplants
• Restraints & Challenges:
• Advent of stem cells
• High costs

Global Organ Preservation Solutions Market: Opportunities

Increasing geriatric population is expected to offer lucrative growth opportunities for players in the global organ preservation market. For instance, according to the U.S. Census Bureau, the U.S. geriatric population is expected to reach 77 million by 2034.        

Moreover, favorable reimbursement scenario is also expected to aid in growth of the global organ preservation market. Currently, almost every transplant procedure is covered under an insurance plan either via Medicare (government insurance) or private insurance players in countries such as the U.S., India, Japan and the U.K.

The global organ preservation solutions market was valued at US$ 204.9 Mn in 2019 and is forecast to reach a value of US$ 695.0 Mn by 2027 at a CAGR of 16.5% between 2020 and 2027.

Market Trends/Key Takeaways

The emergence of Covid-19 is expected to have significant impact on heart and lung transplant. For instance, in August 2020, researchers from University Hospital of Siena, Italy, reported that a higher percentage of lung transplant subjected that Covid-19 could have a negative impact on the outcome of their graft. Moreover, 28% of the patients declared that they were afraid to come to the hospital for routine examinations and asked to postpone.

Increasing funding for development and launch of new solutions is expected to propel growth of the global organ preservation solutions market over the forecast period. For instance, in January 2020, UK and Ireland-focused SME investor BGF provided US$ 6.05 million to OrganOxm, a medtech developer, as the company looks to fund commercial expansion of its Metra unit, a fully-automated system for keeping a human donor liver functioning for up to 24 hours outside the body.

Global Organ Preservation Solutions Market: Competitive Landscape

Major players operating in the global organ preservation market include, Teva Pharmaceutical Industries Ltd., Dr. Franz Köhler Chemie GmbH, BioLife Solutions, XVIVO Perfusion AB, Bristol-Myers Squibb, Inc., and ToleroTech, Inc., Lifeline Scientific, Preservation Solutions Inc., Claris Injectables Limited, 21st Century Medicine, Paragonix Technologies Inc., BioTime, Inc. CryoLife, Inc., and Dr. Franz Köhler Chemie GmbH.

Global Organ Preservation Solutions Market: Key Developments

Major players in the market are focused on approval and launch of new devices to expand their product portfolio. For instance, in February 2020, Paragonix Technologies Inc. received a Pre-Marketing Notification (510(k)) clearance from the US Food and Drug Administration (FDA) for its Donor Lung Preservation System – LUNG guard.

Organ preservation involves removal of organs from the bodies, which are then stored for transplantation. Organ preservation systems are exclusively prepared and maintained according to the biological environment (temperature and oxygen) needed to store particular organs. Different body organs require specific and suitable storage conditions to maintain their anatomical and physiological processes. Important parameters in organ preservation include delivering of high-quality organs to the donors, matching the patient and organ suitability, and restart of life of the organs and sustaining functions after the transplantation. Organ transplantation process starts with removing the needed organ from the donor body, then the organ is stored and transported.

Restraints of the Global Organ Preservation Solutions Market

Major factors hampering the growth of the organ preservation solutions market during the forecast period constitutes of advent of stem cells, and high costs.

Key features of the study:

• This report provides in-depth analysis of the global organ preservation solutions market and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2019–2027), considering 2018, as the base year
• It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by leading players
• It profiles leading players in the global organ preservation solutions market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, strategies, and future plans
• Key companies covered as a part of this study include Teva Pharmaceutical Industries Ltd., Dr. Franz Köhler Chemie GmbH, BioLife Solutions, XVIVO Perfusion AB, Bristol-Myers Squibb, Inc., and ToleroTech, Inc., Lifeline Scientific, Preservation Solutions Inc., Claris Injectables Limited, 21st Century Medicine, Paragonix Technologies Inc., BioTime, Inc. CryoLife, Inc., and Dr. Franz Köhler Chemie GmbH.
• Insights from this report would allow marketers and the management authorities of companies to make informed decision regarding future product launches, technology up-gradation, market expansion, and marketing tactics
• The global organ preservation solutions market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the market.

Detailed Segmentation

• Global Organ Preservation Solutions Market, By Solution Type:
  • Viaspan
  • Custodiol HTK
  • Renograf
  • Hypothermosol
  • Perfadex
  • Lifor
  • HBS Solution
  • siRNA Transplant Solutions
  • Others
• Global Organ Preservation Solutions Market, By Technique Type:
  • Hypothermic Perfusion Preservation
  • Static Cold Storage
  • Others
• Global Organ Preservation Solutions Market, By Geography:
  • North America
    • By Solution Type
      • Viaspan
      • Custodiol HTK
      • Renograf
      • Hypothermosol
      • Perfadex
      • Lifor
      • HBS Solution
      • siRNA Transplant Solutions
      • Others
    • By Technique Type
      • Hypothermic Perfusion Preservation
      • Static Cold Storage
      • Others
    • By Country:
      • S.
      • Canada
    • Europe
      • By Solution Type
        • Viaspan
        • Custodiol HTK
        • Renograf
        • Hypothermosol
        • Perfadex
        • Lifor
        • HBS Solution
        • siRNA Transplant Solutions
        • Others
      • By Technique Type
        • Hypothermic Perfusion Preservation
        • Static Cold Storage
        • Others
      • By Country:
        • K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
      • Asia Pacific
        • By Solution Type
          • Viaspan
          • Custodiol HTK
          • Renograf
          • Hypothermosol
          • Perfadex
          • Lifor
          • HBS Solution
          • siRNA Transplant Solutions
          • Others
        • By Technique Type
          • Hypothermic Perfusion Preservation
          • Static Cold Storage
          • Others
        • By Country:
          • China
          • India
          • Japan
          • ASEAN
          • Australia
          • South Korea
          • Rest of Asia Pacific
        • Latin America
          • By Solution Type
            • Viaspan
            • Custodiol HTK
            • Renograf
            • Hypothermosol
            • Perfadex
            • Lifor
            • HBS Solution
            • siRNA Transplant Solutions
            • Others
          • By Technique Type
            • Hypothermic Perfusion Preservation
            • Static Cold Storage
            • Others
          • By Country:
            • Brazil
            • Mexico
            • Argentina
            • Rest of Latin America
          • Middle East:
            • By Solution Type
              • Viaspan
              • Custodiol HTK
              • Renograf
              • Hypothermosol
              • Perfadex
              • Lifor
              • HBS Solution
              • siRNA Transplant Solutions
              • Others
            • By Technique Type
              • Hypothermic Perfusion Preservation
              • Static Cold Storage
              • Others
            • By Country:
              • GCC
              • Israel
              • Rest of Middle East
            • Africa
              • By Solution Type
                • Viaspan
                • Custodiol HTK
                • Renograf
                • Hypothermosol
                • Perfadex
                • Lifor
                • HBS Solution
                • siRNA Transplant Solutions
                • Others
              • By Technique Type
                • Hypothermic Perfusion Preservation
                • Static Cold Storage
                • Others
              • By Country/Region:
                • Central Africa
                • South Africa
                • North Africa
              • Company Profiles
                • Teva Pharmaceutical Industries Ltd.* 
                  • Company Overview
                  • Product Portfolio
                  • Financial Performance
                  • Key Strategies
                  • Recent Developments
                • Franz Köhler Chemie GmbH
                • BioLife Solutions
                • XVIVO Perfusion AB
                • Bristol-Myers Squibb, Inc.
                • ToleroTech, Inc.
                • Lifeline Scientific
                • Preservation Solutions Inc.
                • Claris Injectables Limited
                • 21st Century Medicine
                • Paragonix Technologies Inc.
                • BioTime, Inc.
                • CryoLife, Inc.